Infant Bacterial Therapeutics today announces that new patent protection is granted in Japan
Infant Bacterial Therapeutics AB today announces that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of NEC and improvement of feeding tolerance in preterm infants.
The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBTs drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU.
The Japanese patent expires in 2036 and the IBP-9414 product covered by this patent is intended to be marketed in Japan after future marketing authorization.
“We are very pleased to strengthen and extend our intellectual property protection for the IBP-9414 product through the approved patent in Japan” says Staffan Strömberg, Chief Executive Officer of IBT.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
111 21 Stockholm
Phone: +46 70 670 1226
This information is information that Infant Bacterial Therapeutics AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 20:00 CET on February 9, 2021.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Baltic Data Center Operators DEAC and DLC Developed a Reliable Business Continuity Solution21.4.2021 09:15:00 CEST | Press release
Data center operator DEAC, in cooperation with the Lithuanian company Data Logistics Center (DLC), pooled their resources and created a disaster recovery solution for enterprises, based on two data centers in Riga (Latvia) and Vilnius (Lithuania). Now DEAC provides its customers with the opportunity to choose the main and backup data center infrastructure location either in Riga or Vilnius. This solution allows businesses to continue their operation even in case of an incident. “The geographic location of two Baltic countries expands the possibilities of data storage and backups in reliable and independent data centers,” comments Andris Gailitis, CEO of DEAC. “It is difficult to foresee the impact of information systems’ failures and recovery times for a company's operations and profits. Therefore, we are taking steps to prevent potential data loss,” adds Darius Zailskas, CEO of DLC. In 2020 both companies were acquired by the Swiss infrastructure investment fund managed by Quaero Capi
PCI Biotech Holding ASA publishes the Annual Report 202021.4.2021 09:05:17 CEST | Press release
Oslo, Norway, April 21, 2021 The Board of Directors of PCI Biotech Holding ASA has approved the Annual Report 2020 and the report is attached. The Annual Report 2020 is also available on the company’s website www.pcibiotech.com. For further information, please contact: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Per Walday, CEO, email@example.com, Mobile: +47 917 93 429 Ronny Skuggedal, CFO, firstname.lastname@example.org, Mobile: +47 940 05 757 About PCI Biotech PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). Photochemical internalisation indu
AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the three months of 202121.4.2021 08:00:00 CEST | Press release
KN invites shareholders, investors, analysts and other stakeholders to join its investor conference webinar scheduled on theApril 30th of 2021 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Jonas Lenkšas who will introduce the performance and unaudited financial results of KN for the three months of 2021. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until July 28th to email@example.com How to join the webinar? To join the webinar, please register via following link:https://register.gotowebinar.com/register/7211612518603224845You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in c
Enento Group’s CEO Jukka Ruuska leaves the company21.4.2021 08:00:00 CEST | Press release
ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 21 APRIL 2021 AT 9.00 A.M. EEST Enento Group’s CEO Jukka Ruuska leaves the company Enento Group Plc’s CEO Jukka Ruuska has given notice of his resignation from the company. The Group’s Board of Directors will start the recruiting process of a new CEO immediately. Jukka Ruuska will continue in his position until his successor will start, however no later than 31 October 2021. “After nearly a decade as CEO, it’s time for personal renewal and time to move towards new. It has been a great opportunity to develop Asiakastieto to Enento Group together with great Enento employees committed to business development. I am proud of the results we have achieved and would like to thank all my excellent colleagues. Meeting customers is one of the best parts of this work and I want to express my gratitude to our customers for the opportunity for a real dialogue”, says Jukka Ruuska, CEO of the Enento Group. “I would like to thank Jukka for his significant con
Positive results despite impact of Covid-19 and strained competitive environment21.4.2021 07:00:00 CEST | Press release
Press release Embargo until 21 April 2021 at 7:00 am Regulated information – Inside information Financial information for the first quarter 2021 Positive results despite impact of Covid-19 and strained competitive environment Mobile postpaid customer base +3.0% yoy / Cable customer base +24.8% yoyQ1 Revenues -1.0% yoy / Q1 Retail service revenues +1.9% yoy Q1 EBITDAaL+12.8% yoy, +4.6% yoy excluding seasonality effect 2021 guidance confirmed Q1 Operational HighlightsCommercial performance remained solid amid a tougher competitive environment and on-going Covid-19 measures that limited the shops’ full capacity. Go portfolio remains a success, with Go Unlimited special edition gaining traction. During the quarter, 23k new mobile postpaid customers were added, reaching 2.7m subscribers (+3.0% yoy). Cable net adds continued to be strong with 23k new customers. One third of the gross adds are Love Duo customers, confirming the commercial trend of former quarters. Convergent mobile subscriber
Kitron: Electrification and Industry sectors drive revenue growth21.4.2021 07:00:00 CEST | Press release
(2021-04-21) Kitron today reported quarterly figures showing strong growth within the market sectors Electrification and Industry. Kitron’s revenue for the first quarter was NOK 938 million, an increase of 7 per cent compared to last year. Profitability expressed as EBIT margin was 7.0 per cent in the first quarter, compared to 6.7 per cent in the same quarter last year. Peter Nilsson, Kitron's CEO, comments: “We continue to capitalize on two of the most fundamental changes in the global economy: the move to renewable energy and electrification and the rapid growth in machine-to-machine communications. The demand is very strong. However, as the general material supply situation is challenging, Kitron’s operations will have to be flexible to deliver the demand. In general, the first quarter demonstrates that Kitron’s growth follows the strategic path we outlined at our capital markets presentation in March.” Increased revenue Kitron’s revenue for the first quarter was NOK 938 million, c
To the Shareholders of Cavotec SA: Notice of Annual General Meeting21.4.2021 07:00:00 CEST | Press release
The AGM will take place Thursday, May 27, 2021, 14:00 CEST at Cavotec SA headquarters in Lugano, Switzerland (Via G.B. Pioda 14, Lugano). IMPORTANT COMMUNICATION:no personal attendance and exercise of rights exclusively through the Independent Proxy In view of the current situation involving the spread of the Covid-19, it will not be possible to attend the Annual General Meeting in person. As a result, the Board of Directors based on art. 27 of the Ordinance 3 on Measures to Combat the Coronavirus (COVID-19; SR 818.101.24 of 19 June 2020 – Status as of 15 April 2021) decided that the shareholders of Cavotec SA may exercise their rights at the Annual General Meeting exclusively through the Independent Proxy. For more information regarding the appointment of the Independent Proxy please refer to the “Participation” section below. AGENDA AND PROPOSALS OF THE BOARD OF DIRECTORS 1. Appointment of the Chairman of the day According to the Art. 11 of the Articles of Association, general meetin